StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.56+0.06 (+0.29%)

Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%

Damora Therapeutics cash

Cash and short-term investments held at the end of each period.

Damora Therapeutics's cash was $528.48M at Sep 30, 2026. For fiscal 2025 it was $257.62M, up 1717.5% from the year before. The highest annual figure on record is $257.62M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$257.62M+1717.5%
FY2024Dec 31, 2024$14.18M-57.2%
FY2023Dec 31, 2023$33.15M-45.0%
FY2022Dec 31, 2022$60.22M-39.9%
FY2021Dec 31, 2021$100.19M-38.8%
FY2020Dec 31, 2020$163.84M+1321.6%
FY2019Dec 31, 2019$11.53M-63.0%
FY2018Dec 31, 2018$31.13M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$528.48M+6848.2%
Q2 FY2026Jun 30, 2026$540.52M+5193.5%
Q1 FY2026Mar 31, 2026$532.90M+4363.5%
Q4 FY2025Dec 31, 2025$257.62M+1717.5%
Q3 FY2025Sep 30, 2025$7.61M-61.3%
Q2 FY2025Jun 30, 2025$10.21M-55.3%
Q1 FY2025Mar 31, 2025$11.94M-56.1%
Q4 FY2024Dec 31, 2024$14.18M-57.2%
Q3 FY2024Sep 30, 2024$19.68M-55.5%
Q2 FY2024Jun 30, 2024$22.86M-56.1%
Q1 FY2024Mar 31, 2024$27.17M-49.0%
Q4 FY2023Dec 31, 2023$33.15M-45.0%
Q3 FY2023Sep 30, 2023$44.18M-36.1%
Q2 FY2023Jun 30, 2023$52.12M-34.0%
Q1 FY2023Mar 31, 2023$53.25M-43.1%
Q4 FY2022Dec 31, 2022$60.22M-39.9%
Q3 FY2022Sep 30, 2022$69.08M-32.4%
Q2 FY2022Jun 30, 2022$79.03M-22.4%
Q1 FY2022Mar 31, 2022$93.60M-15.2%
Q4 FY2021Dec 31, 2021$100.19M-38.8%
Q3 FY2021Sep 30, 2021$102.14M+19.7%
Q2 FY2021Jun 30, 2021$101.81M+184.1%
Q1 FY2021Mar 31, 2021$110.33M+157.9%
Q4 FY2020Dec 31, 2020$163.84M+1321.6%
Q3 FY2020Sep 30, 2020$85.33M+480.7%
Q2 FY2020Jun 30, 2020$35.84M+15.1%
Q1 FY2020Mar 31, 2020$42.78M–
Q4 FY2019Dec 31, 2019$11.53M–
Q3 FY2019Sep 30, 2019$14.70M–
Q4 FY2018Dec 31, 2018$31.13M–

More Damora Therapeutics figures

See a number that looks wrong?